This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

UCB And IBM Collaborate To Personalize Care For Epilepsy Patients

ARMONK, N.Y. and BRUSSELS, May 16, 2013 /PRNewswire/ -- regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessing the transformative power of cognitive computing capabilities, such as IBM Watson, for epilepsy care.

The goal of the project is to deliver an interactive system that translates massive amounts of patient data and scientific literature into insights that healthcare providers can consult at the point of care to inform their treatment decisions.

Together, UCB and IBM scientists are working to create the healthcare industry's most comprehensive corpus of data on epilepsy. Upon completion of this project, healthcare providers would be able to combine their own clinical patient assessment with the system's predictive analytics to determine the probability that specific approaches to care will be successful.

Dr. Iris Low-Friedrich, Executive Vice-President Global Projects and Development and Chief Medical Officer, UCB said: "UCB focuses on the creation of innovative networks because we recognize that delivering best-in-class solutions to patients requires collaboration with a diverse group of internal and external experts. We have partnered with IBM to explore this concept of streamlining large amounts of data into actionable approaches to epilepsy care."

Epilepsy, one of the most common diseases of the central nervous system, afflicts approximately 65 million people worldwide 1. A recent special issue of The Lancet 2 highlighted the significant unmet medical needs in epilepsy and called on public health officials to treat this disease as a global health priority.

UCB and IBM anticipate that deeper insight into the epilepsy patient population could potentially provide millions of patients with more personalized care and ultimately improved outcomes. This approach will help seed the foundation for the potential to leverage cognitive computing, natural language processing, and machine learning capabilities to raise the standard of care in epilepsy.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs